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Clinical Presentation   
A 66-year-old man presented to the emergency 
department with tremors, dyspnea, nausea, poly-
arthralgia, and dysuria. He had a history of 
hypertension and ischemic heart disease. His medica-
tions included amlodipine, ramipril, and low-dose 
aspirin.  
At admission, the patient was sweaty and showed 
generalized tremors. Blood pressure was 210/110 mm 
Hg, heart rate was 80 beats/min, and axillary 
temperature was 36.5 C. Physical examination showed 
diffuse muscle tenderness, mild peripheral edema, and 
basal pulmonary rales, with normal heart sounds. 
Laboratory studies showed elevated serum creatinine 
(201.5 μmol/L), urea nitrogen (10.3 mmol/ L), 
transaminase (aspartate aminotransferase, 3,488 U/ L; 
and alanine aminotransferase, 746 U/L), and lactate 
dehydrogenase levels (3,416 U/L), along with marked 
elevation of serum creatinine kinase (CK) level 
(167,000 U/L). Serum potassium level was 3.6 mmol/ 
L; calcium, 2 mmol/L; and phosphate, 1.6 mmol/L. 
Urine dipstick was positive for blood and leukocyte 
esterase; microscopic examination of urine showed 
only about 2 red blood cells per high-power field.  
A diagnosis of severe rhabdomyolysis was made. 
Shortly after admission, the patient’s condition 
worsened and he was transferred to the intensive care 
unit. An echocardiogram documented severely 
depressed right and left ventricular function (ejection 
fraction, 20%) with generalized hypokinesis. Elec-
tromyography showed the presence of severe 
muscular injury without evidence of acute denerva-
tion. The patient developed oliguric acute kidney 
injury (AKI), and continuous renal replacement 
therapy (CRRT) was initiated.  
Further history revealed that the patient had 
recently been engaged in what was for him unusually 
intense physical activity. It was also learned that he 
had presented with a similar episode of muscle 
damage 6 years before, when after coronary artery 
bypass surgery, he developed a marked in-crease in 
CK levels (27,000 U/L) that was not asso-ciated with 
AKI.  
In the following days, respiratory and cardiac con-
ditions improved, while kidney injury persisted and 
the patient was switched from CRRT to hemodialysis 
ther-apy. Two weeks after admission, kidney function 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Skeletal muscle biopsy specimen shows small 
intracytoplasmic vacuoles (arrows) with (A) hematoxylin 
and eosin stain and (B) confirming the presence of lipid 
droplets (arrows) with Oil Red O stain (original 
magnification, ×400).  
 
improved and hemodialysis treatments were dis-
continued. Extensive testing was performed to 
elucidate the cause of the muscle injury, including a 
muscle biopsy (Fig 1).  
 
• What is the differential diagnosis of the under-
lying cause of rhabdomyolysis in patients such as 
this? 
 
• What are the effects of rhabdomyolysis on 
kidney function? 
 
• What is the optimal management of patients 
with AKI secondary to rhabdomyolysis? 
 
 
 
 
 
 
 Discussion   
What is the differential diagnosis of the underlying 
cause of rhabdomyolysis in patients such as this? 
 
Rhabdomyolysis may result from trauma, extreme 
physical exercise, prolonged immobilization associated 
with compression and ischemic injury, hypo-
phosphatemia, drugs (mainly alcohol, opioids, and 
statins), infections, hypokalemia, certain autoimmune 
diseases, endocrine abnormalities such as hypo- or 
hyperthyroidism, hypothermia, and hyperthermia. 
Massive muscle damage can also occur in some genetic 
disorders affecting muscle structure and energy meta-
bolism, such as glycogen storage diseases, muscular 
dystrophies, disorders of fatty acid metabolism, and 
mitochondrial diseases. Clinically, muscle injury may be 
asymptomatic or present as local or diffuse pain, 
tenderness, or weakness and may be associated with 
nonspecific symptoms, including fatigue, nausea, 
vomiting, and fever. Patients may report red or brown 
urine. The most specific laboratory marker of rhabdo-
myolysis is elevated plasma CK level, with values from 
5 to 10 times the upper limit of normal frequently used to 
define rhabdomyolysis. Other markers of rhabdomyol-
ysis include elevated lactate dehydrogenase and serum 
transaminase levels and the presence of myoglobinuria. 
Myoglobinuria is typically diagnosed by the presence of 
a very positive urine dipstick test for blood, with 
disproportionately few red blood cells in urine. Urine 
myoglobin can also be directly measured.  
When a diagnosis of rhabdomyolysis has been 
established, patients should be queried regarding any 
history of unusual recent physical activity, trauma, 
prolonged immobilization, infections, use of illicit drugs 
or those associated with rhabdomyolysis, and any 
pertinent personal prior or family history of muscle 
injury. A family history of rhabdomyolysis or history of 
recurrent episodes consistent with rhabdomyolysis is 
suggestive of genetic myopathies.
1
 Laboratory studies 
should include assessment of mineral metabolism, 
glucose metabolism, and autoimmunity markers such as 
myositis-specific autoantibodies and myositis-associated 
autoantibodies, including anti-Jo-1, anti-signal recog-
nition particle, anti-Mi-2, anti-PM-Scl, and anti-SS-A/Ro 
antibodies. Finally, muscle biopsy may be diagnostically 
helpful in select cases of unexplained or recurrent 
rhabdomyolysis.  
In this patient, a muscle biopsy performed 22 days 
after the acute muscle injury did not shown evidence of 
inflammation or acute muscle damage, such as fiber 
necrosis or ghost fibers, but revealed mild fiber size 
variability and multiple small vacuoles in numerous 
muscle fibers. The vacuoles were filled with lipid 
droplets as shown by Oil Red O stain (Fig 1). The 
presence of lipid-rich vacuoles along with mild fiber 
 
 
size variability was thought to be indicative of a meta-
bolic myopathy. In particular, such lesions have been 
described in cases of carnitine palmitoyltransferase II 
(CPT II) deficiency, sometimes as the only abnormal 
finding, because muscle histology in CPT II 
deficiency is usually normal. Biochemical analysis of 
muscle CPT II showed decreased enzyme activity, and 
subsequent genetic analysis showed a homoplasmic 
mutation in the CPT II gene (a substitution of cytosine 
by thymine at nucleotide 338 of the coding sequence, 
corresponding to a serine to leucine change at amino 
acid 113 [c.338C>T, p.Ser113Leu]), definitively 
confirming the diagnosis of CPT II deficiency.2 
 
What are the effects of rhabdomyolysis on 
kidney function? 
 
AKI develops in 10% to 40% of patients with severe 
rhabdomyolysis. No single factor, including levels of 
serum CK, creatinine, potassium, calcium, or myoglo-
binuria, accurately predicts AKI in patients with rhab-
domyolysis. However, patients with muscle injury 
secondary to trauma, especially in the presence of co-
morbid conditions, are at major risk for AKI 
compared with patients with elevated CK levels 
secondary to intensive exercise, use of statins, 
infections, or inflam-matory myopathies.  
The main mechanism of kidney damage in patients 
with rhabdomyolysis is the massive release of 
myoglobin into the circulation, with myoglobinuria.3 
Myoglobinuria, which becomes visible when urine 
myoglobin excretion exceeds 100 to 300 mg/dL, 
causes cast formation and accumulation of iron in 
proximal tubules, with intratubular obstruction and 
proximal tubular cell injury. Another factor involved 
in the pathogenesis of acute tubular injury and AKI 
includes volume depletion due to sequestration (“third 
spacing”) of fluids into injured muscles. Release of 
cellular constituents from damaged muscles can lead 
to high anion gap metabolic acidosis, hyperkalemia, 
hyperphosphatemia, and hyperuricemia. 
Hypocalcemia is commonly seen as the result of 
calcium deposition in damaged muscles. Metabolic 
acidosis and the resulting aciduria might further 
exacerbate tubular damage because at low urinary pH, 
myoglobin dissociates into globin and ferrihemate, 
which has a direct nephrotoxic effect. 
 
What is the optimal management of patients 
with AKI secondary to rhabdomyolysis? 
 
The mainstays of efforts to prevent AKI in patients with 
rhabdomyolysis are saline solutions to expand/restore 
intravascular volume and treatment of the underlying 
cause of rhabdomyolysis. Although there is general 
agreement on early and aggressive volume resuscitation 
aimed at increasing urine flow (about 200-300 mL/h), 
there is no strong evidence about the best types of fluids 
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to administer. The rationale for using sodium bicar-
bonate infusions rather than isotonic saline solutions 
is that urinary alkalization could avoid myoglobin pre-
cipitation and inhibit reduction–oxidation cycling of 
myoglobin and lipid peroxidation. However, although 
widely used, this approach is not evidence based and 
may increase the risk for metastatic tissue 
calcification and ionized hypocalcemia. The use of 
diuretics (ie, mannitol or furosemide) to increase 
diuresis has not been tested in clinical studies and is 
not generally recommended.  
Various forms of dialytic therapy have been used if 
AKI develops, but there is no evidence supporting the 
use of a specific dialysis modality. Dialysis has also been 
hypothesized to enhance recovery through removal of 
myoglobin released into the circulation from injured 
muscles. Although some hemodialysis and CRRT filter 
membranes can remove myoglobin, there is little 
evidence that this is beneficial after AKI has been 
established. Intermittent hemodialysis is generally 
ineffective in sustaining a reduction in plasma 
myoglobin levels because of rapid rebound in levels 
following a single hemodialysis treatment. CRRT or 
hemofiltration is more effective, with much greater 
clearance of myoglobin than conventional filters,
1,3
 but 
again, without evidence that this prevents AKI or 
improves its subsequent course once developed. In the 
current case, because of oliguria and severe AKI, 
continuous venovenous hemodiafiltration therapy with a 
high-flux membrane (AN69; Hospal Medical) was 
initiated. After 5 days, CK levels decreased to 22,000 
U/L. Two weeks after admission, the patient was 
switched from CRRT to intermittent hemodialysis 
therapy. In the following days, diuresis ensued and 
kidney function progressively improved, so that it was 
possible to withdraw hemodialysis therapy.  
CPT II deficiency is a rare disorder of the fatty acid 
beta-oxidation cycle, caused by homozygous or 
compound heterozygous mutations in the CPT2 
gene.4 CPT II works as a shuttle for long-chain fatty 
acids to enter mitochondria, where they are used as 
the main energy source of muscles during prolonged 
exercise. CPT II deficiency leads to ATP depletion 
and dysfunc-tion of the adenosine triphosphatase 
sodium/potassium pump (Na+/K+-ATPase) and the 
calcium-transporting adenosine triphosphatase (Ca2+-
ATPase) and activates phospholipases and proteases, 
which lyse cellular membranes and disrupt 
mitochondrial function. Diagnosis of CPT II 
deficiency, when clinically suspected, is confirmed by 
a combination of enzyme assay and molecular genetic 
testing for pathogenic mutations in the CPT2 gene.  
This patient represents a typical case of CPT II 
deficiency, with a history of recurrent rhabdomyol-
ysis exacerbated by physical activity and postsurgery 
stress. After resolution of the AKI, prophylactic 
 
 
measures consist of preventing muscle energy 
depletion by avoiding intense physical activities. 
Following this recommendation, the patient did not 
develop other rhabdomyolysis episodes during 2 years 
of follow-up, at which time serum creatinine level was 
111.8 μmol/L and CK (51 U/L) and myoglobin (65 
ng/mL) levels were within the reference ranges.  
 
 
 
Final Diagnosis   
Acute kidney injury caused by rhabdomyolysis due to 
a mutation in the gene for the carnitine 
palmitoyltransferase II enzyme.  
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